Download PDF
Thromb Haemost 1998; 80(04): 607-609
DOI: 10.1055/s-0037-1615430
Rapid Communication
Schattauer GmbH

The Risk of Mortality and the Factor V Leiden Mutation in a Population-based Cohort

Bastiaan T. Heijmans
1   From the Gaubius Laboratory, TNO Prevention and Health, Leiden, The Netherlands
2   From the Section of Gerontology and Geriatrics, Department of General Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
,
Rudi G. J. Westendorp
2   From the Section of Gerontology and Geriatrics, Department of General Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
3   From the Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
,
Dick L. Knook
1   From the Gaubius Laboratory, TNO Prevention and Health, Leiden, The Netherlands
2   From the Section of Gerontology and Geriatrics, Department of General Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
,
Cornelis Kluft
1   From the Gaubius Laboratory, TNO Prevention and Health, Leiden, The Netherlands
,
Eline P. Slagboom
1   From the Gaubius Laboratory, TNO Prevention and Health, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 08 May 1998

Accepted after resubmission 23 June 1998

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Summary

The factor V Leiden mutation (conferring resistance to activated protein C) has been implicated in the risk of arterial thrombosis and is a well-established risk factor for venous thrombosis especially in the elderly. We studied whether the disease association of the factor V mutation is reflected in an increased all-cause and cause-specific mortality.

First, the prevalence of the factor V Leiden mutation was determined in a population-based study among subjects aged 85 years and over (4.7%, n = 660) and was found to correspond to the prevalence in young subjects aged 18 to 40 years (5.0%, n = 321). Secondly, we studied the association of factor V Leiden with the risk of all-cause mortality and specific causes of death in the elderly cohort during a 10-year follow-up period. Neither the all-cause mortality risk (RR 1.0; 95% CI, 0.7-1.5), nor the risk of death due to cardiovascular disease (RR 0.9; 95% CI, 0.5-1.7) were increased in elderly subjects heterozygous for factor V Leiden. Our study thus indicates that heterozygosity for factor V Leiden does not affect population mortality.

 

  • References

  • 1 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
    CrossrefPubMedGoogle Scholar
  • 2 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Eng J Med 1995; 332: 912-7.
    CrossrefPubMedGoogle Scholar
  • 3 Griffin JH, Heeb MJ, Kojima Y, Fernandez JA, Kojima K, Hackeng TM, Greengard JS. Activated protein C resistance: molecular mechanisms. Thromb Haemost 1995; 74: 444-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, Aiach M, Cambien F. Myocardial infarction, Arg 506 to Gln factor V mutation and activated protein C resistance. Lancet 1995; 345: 321.
    CrossrefPubMedGoogle Scholar
  • 5 Van Bockxmeer FM, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V. Nature Med 1995; 1: 185.
    CrossrefPubMedGoogle Scholar
  • 6 Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Long-streth WT, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-21.
    PubMedGoogle Scholar
  • 7 Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennekens CH. Age-specific incidence rates of venous thrombosis among heterozygous carriers of factor V Leiden mutation. Ann Int Med 1997; 126: 528-31.
    CrossrefPubMedGoogle Scholar
  • 8 Lagaay AM, D’Amaro J, Ligthart G J, Schreuder G M T, Van Rood JJ, Hijmans W. Longevity and heredity in humans: Association with Human Leucocyte Antigen phenotype. Ann N Y Acad Sci 1991; 621: 78-89.
    CrossrefPubMedGoogle Scholar
  • 9 Weverling-Rijnsburger AWE, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RGJ. Total cholesterol and the risk of mortality in the oldest old. Lancet 1997; 350: 1119-23.
    CrossrefPubMedGoogle Scholar
  • 10 Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of the factor V Leiden mutation. Lancet 1994; 344: 1453-7.
    CrossrefPubMedGoogle Scholar
  • 11 Manten B, Westendorp RGJ, Koster T, Reitsma PH, Rosendaal FR. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost 1996; 76: 510-3.
    PubMedGoogle Scholar
  • 12 Martinelli I, Cattaneo M, Panzeri D, Mannucci PM. Low prevalence of Factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost 1997; 77: 440-3.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Baglin TP, Brown K, Williamson D, Baker P, Luddington R. Relative risk of pulmonary embolism and deep vein thrombosis in association with the factor V Leiden mutation in a United Kingdom population. Thromb Haemost 1997; 77: 1219.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Vandenbroucke JP, Bertina RM, Holmes ZR, Spaargaren C, Van Krieken JHJM, Manten B, Reitsma PH. Factor V Leiden and fatal pulmonary embolism. Thromb Haemost 1998; 79: 511-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Hille ETM, Westendorp RGJ, Vandenbroucke JP, Rosendaal FR. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood 1997; 89: 1963-7.
    PubMedGoogle Scholar
  • 16 Mari D, Mannucci PM, Duca F, Bertolini S, Franceschi C. Mutant factor V (Arg506Gln) in healthy centenarians. Lancet 1996; 347: 1044.
    PubMedGoogle Scholar
  • 17 Faure-Delanef L, Quéré I, Zouali H, Cohen D. Human longevity and R506Q factor V gene mutation. Thromb Haemost 1997; 78: 1160.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993; 153: 1557-62.
    CrossrefPubMedGoogle Scholar